Company intelligence / Profile preview

Cove

Ownership: Private
Development stage: Other

Overview

Cove provides telemedicine-based access to clinically proven prescription medications and personalized treatment plans for migraine sufferers. Over 2.4 million migraine attacks have been treated through their platform, with high patient satisfaction rates and significant improvements in quality of life reported. "75% of Cove patients report a reduction in headache intensity...90% are satisfied with the treatment they receive." The company does not conduct its own clinical trials but relies on established therapies.

Therapeutic areas: Neurology
Modalities: Small moleculeDevice
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Cove.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cove.

Explore the full profile